Kumquat Biosciences

Executive Summary

Kumquat Biosciences is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics targeting the KRAS pathway, a key driver in multiple cancers. Founded in 2020 and headquartered in San Diego, the company aims to deliver durable treatment options for patients with KRAS-mutant tumors. While specific pipeline details are limited, the company's expertise in KRAS biology positions it within a highly competitive but promising field. The company is privately held and has not disclosed financing or valuation data. Its early-stage status and lack of public data suggest a high-risk, high-reward profile, with potential for significant value creation if clinical programs succeed. The KRAS-targeting space has seen recent breakthroughs (e.g., sotorasib, adagrasib), but also intense competition and high failure rates. Kumquat's differentiated approach, if any, is not publicly known; however, its focus on small molecules and KRAS suggests it may pursue novel inhibitors or combination strategies. Overall, the company's prospects hinge on preclinical/clinical data readouts and its ability to secure partnerships or funding.

Upcoming Catalysts (preview)

• Q2 2026Phase 1/2 Clinical Data Readout for Lead KRAS Inhibitor20% success
• 2026Series A or B Financing Announcement60% success
• Q4 2026IND Filing for Second-Generation KRAS Inhibitor50% success